Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Lung Cancer Année : 2020

Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project

Roger Lacave
  • Fonction : Auteur
Alexandra Langlais
Pascale Missy
  • Fonction : Auteur
Franck Morin
  • Fonction : Auteur
Jacques Cadranel
  • Fonction : Auteur
  • PersonId : 901162

Résumé

T790M mutations inEGFR-mutated non-small cell lung cancer (NSCLC) account for nearly 50% of acquired resistance mechanisms to EGFR-TKIs. Earlier studies suggested that tumor T790M could also be detected in TKI-naïve EGFR-mutated NSCLC. The aim of the study is to assess the prevalence and clinical significance of quantification of tumor pre-treatment T790M subclones.

Dates et versions

hal-02504797 , version 1 (11-03-2020)

Identifiants

Citer

Michèle Beau-Faller, Erwan Pencreach, Charlotte Leduc, Hélène Blons, Jean-Philippe Merlio, et al.. Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project. Lung Cancer, 2020, 140, pp.19-26. ⟨10.1016/j.lungcan.2019.10.013⟩. ⟨hal-02504797⟩
137 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More